{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.11","value":"2.20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"The Dyspareunia Subscale Score on the Female Sexual Dysfunction Index ranges from 0-5 with higher scores indicating better sexual function, so less dyspareunia.","dispersionType":"Standard Deviation","groups":[{"description":"Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).","id":"OG000","title":"Intrarosa & Standard of Care Aromatase Inhibitor"},{"description":"Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).","id":"OG001","title":"Replens & Standard of Care Aromatase Inhibitor"}],"paramType":"MEAN","populationDescription":"Out of 8 participants assigned to a treatment arm, only 2 took the FSFI at both the baseline and 12-week visits.","reportingStatus":"POSTED","timeFrame":"12 weeks (±1 week)","title":"Difference in Dyspareunia Subscale Scores on the Female Sexual Dysfunction Index (FSFI) From Baseline to Week 12","type":"SECONDARY","unitOfMeasure":"Units on a scale"}